Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes OBJECTIVE. Patients with type 2 diabetes (T2D) are at increased risk of acute pancreatitis (AP) and biliary events. Evidence remains mixed regarding the as

En pacientes con diabetes tipo 2, los GLP-1RA y los DPP-4i se asocian con un pequeño aumento en el riesgo de enfermedad biliar pero no de pancreatitis aguda, comparados con los SGLT2i #SGLT2is #GLP1RA #dpp4i #t2d diabetesjournals.org/care/article...

#SGLT2i might provide cardiorenal protection among older adults with dementia and diabetes compared with #DPP4i, but close monitoring needed due to greater susceptibility to #DKA #DiabetesResearch

GLP-1 Receptor Agonist Use Linked to Lower Mortality in Older Adults With Cancer, T2D GLP-1 RA use is associated with lower all-cause mortality than DPP4i use in older patients with cancer and type 2 diabetes.

No difference in mortality risk was seen for #GLP-1 RA and SGLT2i users; significantly lower risk was seen for GLP-1 RA vs #DPP4i users.

Read More: https://bit.ly/4maoFiC

SGLT2 Inhibitor Use Linked to Increased Risk for Erythrocytosis, Not Thrombosis SGLT2 inhibitor use was associated with an increased risk for erythrocytosis but not thrombosis among patients with type 2 diabetes.

Relative to #GLP1RA and #DPP4i use, #SGLT2i use was associated with an increased risk for #erythrocytosis but not an increased risk for #thrombosis in #T2D.

Risk for Angioedema with the Use of Dipeptidyl Peptidase 4 Inhibitors: A Population-Based Cohort Study Dipeptidyl peptidase 4 (DPP4) inhibitors, which are widely used antidiabetic medications, may induce the accumulation of bradykinin and substance P, a…

Uso de inhibidores de la DPP4 sin uso concomitante de IECA no se asocia con un mayor riesgo de angioedema comparados con otros hipoglucemiantes de segunda generación #angioedema #DPP4i www.sciencedirect.com/science/arti...

Use of SGLT2i Versus DPP-4i as an Add-On Therapy and the Risk of PAD-Related Surgical Events (Amputation, Stent Placement, or Vascular Surgery): A Cohort Study in Veterans With Diabetes OBJECTIVE. To compare the risk of composite peripheral artery disease (PAD) surgical outcome, including peripheral revascularization and amputation procedu

Uso de inhibidores SGLT2 agregados a la terapia para la diabetes se asocia con un mayor riesgo de cirugía por enfermedad arterial periférica que los inhibidores DPP4 #PAD #SGLT2i #DPP4i diabetesjournals.org/care/article...

Use of SGLT2i Versus DPP-4i as an Add-On Therapy and the Risk of PAD-Related Surgical Events (Amputation, Stent Placement, or Vascular Surgery): A Cohort Study in Veterans With Diabetes OBJECTIVE. To compare the risk of composite peripheral artery disease (PAD) surgical outcome, including peripheral revascularization and amputation procedu

Inhibidores SGLT2 añadidos a la terapia para la diabetes se asocian con un riesgo mayor de cirugía por enfermedad arterial periférica comparados con los inhibidores DPP4 #DPP4i #SGLT2i #PAD diabetesjournals.org/care/article...

Study shows oral semaglutide matches DPP-4i in adherence and persistence for type 2 diabetes Researchers found that adherence and persistence in T2D patients using oral semaglutide is similar to DPP-4i, but semaglutide users required fewer concurrent medications, indicating higher long-term e...

Study shows oral semaglutide matches DPP-4i in adherence and persistence for type 2 diabetes 📊💊🔬 www.news-medical.net/news/2024071... #Diabetes #Type2Diabetes #Semaglutide #DPP4i #Adherence #Persistence #Pharmacotherapy #Healthcare #Medical